ScinoPharm Taiwan
ScinoPharm Taiwan is a CDMO of peptides based in Taiwan (Tainan). Direct manufacturer. Founded 1997. Key products include peptide APIs, generic APIs.
Listing reviewed October 2026.
About ScinoPharm Taiwan
Taiwanese API manufacturer and CDMO focused on complex generic APIs, including peptides and oncology compounds. Holds active US Drug Master Files for liraglutide and semaglutide API.
Directory assessment: ScinoPharm Taiwan is listed as a CDMO in the peptide supply chain, serving Asia markets from Taiwan (Tainan). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.
- Semaglutide: DMF 42296 (Type II, active), submitted 2025-12-10
- Liraglutide: DMF 37009 (Type II, active), submitted 2022-05-19
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-15.